Blend
BPC-157 / TB-500
Custom strengths on request
Compounded medications are not FDA-approved.
What is in the vial
Blend calculator
Blend vial
Pick the blend, then the one component your dose is written for. The others follow from the vial.
Result
Draw to
-
- Water in the vial
- -
- Dose anchored to
- BPC-157
What each component delivers
| Component | Delivered |
|---|---|
| BPC-15710 mg in the vial | - |
| TB-50010 mg in the vial | -No established dose |
Math on the numbers above. Not medical advice; confirm concentration against the dispensed vial label.
Each component at a glance
BPC-157
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
Start
10 mg (total), injected around the inflamed bladder area during cystoscopy
Human study
- Frequency
- Single procedure
- Route
- Around bladder inflammation during cystoscopy (reported as intravesical)
- Course
- Single administration; follow-up duration not stated
TB-500
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
No established human dose
No human or animal efficacy study of TB-500 (Ac-LKKTETQ) itself was identified. Trade press reports that FDA acknowledged 'there are no studies on TB500 itself'. Published work on the fragment is analytical, rat metabolism and in-vitro. Human trials exist only for full-length thymosin beta-4: an IV phase 1 study in healthy volunteers, ophthalmic RGN-259 dry-eye phase 2 trials (mixed efficacy, no safety issues reported), and topical dermal phase 2 trials in stasis and pressure ulcers. These data do not establish TB-500 dosing, safety or efficacy. Related full-length work not used for dosing includes a venous-ulcer design report and a recombinant human Tbeta4 STEMI study.
Get a quote
Custom strengths on request. Prices are quoted per clinic.